Osimertinib tolerance in a patient with Stevens Johnson syndrome during osimertinib therapy after treatment with pembrolizumab
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- Umfang
-
1 Online-Ressource.
- Sprache
-
Englisch
- Erschienen in
-
Osimertinib tolerance in a patient with Stevens Johnson syndrome during osimertinib therapy after treatment with pembrolizumab ; volume:19 ; number:1 ; day:28 ; month:10 ; year:2023 ; pages:1-4 ; date:12.2023
Allergy, asthma and clinical immunology ; 19, Heft 1 (28.10.2023), 1-4, 12.2023
- Klassifikation
-
Medizin, Gesundheit
- Urheber
-
Lopez, Michael
Hagopian, Garo
Doan, Linda
Lee, Benjamin J.
Rojek, Nathan W.
Smith, Janellen
Ou, Sai-Hong
Demirdag, Yesim Yilmaz
Nagasaka, Misako
- Beteiligte Personen und Organisationen
-
SpringerLink (Online service)
- DOI
-
10.1186/s13223-023-00849-5
- URN
-
urn:nbn:de:101:1-2024011608304170969430
- Rechteinformation
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
15.08.2025, 07:27 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Lopez, Michael
- Hagopian, Garo
- Doan, Linda
- Lee, Benjamin J.
- Rojek, Nathan W.
- Smith, Janellen
- Ou, Sai-Hong
- Demirdag, Yesim Yilmaz
- Nagasaka, Misako
- SpringerLink (Online service)
Ähnliche Objekte (12)
Successful Rechallenge with Osimertinib following Osimertinib-Induced Ventricular Tachycardia: A Case Report
Osimertinib and palbociclib in an EGFR-mutated NSCLC with primary CDK4 amplification after progression under osimertinib
Editorial-T790M mutation and clinical outcomes with genuine osimertinib
Osimertinib in combination with anti-angiogenesis therapy presents a promising option for osimertinib-resistant non-small cell lung cancer
Correction: Osimertinib in combination with anti-angiogenesis therapy presents a promising option for osimertinib-resistant non-small cell lung cancer
Successful osimertinib rechallenge in a patient with advanced non-small cell lung cancer following osimertinib-induced interstitial lung disease after treatment with nivolumab
Osimertinib (Lungenkarzinom): Nutzenbewertung gemäß § 35a SGB V
Osimertinib-induced interstitial lung disease after treatment with anti-PD1 antibody
Therapeutic effect of osimertinib plus cranial radiotherapy compared to osimertinib alone in NSCLC patients with EGFR-activating mutations and brain metastases: a retrospective study
Afatinib plus osimertinib in the treatment of osimertinib-resistant non-small cell lung carcinoma: a phase I clinical trial
Osimertinib (NSCLC, adjuvant) : Nutzenbewertung gemäß § 35a SGB V
Osimertinib in Indian patients with T790M-positive advanced nonsmall cell lung cancer
Successful Rechallenge with Osimertinib following Osimertinib-Induced Ventricular Tachycardia: A Case Report
Osimertinib and palbociclib in an EGFR-mutated NSCLC with primary CDK4 amplification after progression under osimertinib
Editorial-T790M mutation and clinical outcomes with genuine osimertinib
Osimertinib in combination with anti-angiogenesis therapy presents a promising option for osimertinib-resistant non-small cell lung cancer
Correction: Osimertinib in combination with anti-angiogenesis therapy presents a promising option for osimertinib-resistant non-small cell lung cancer
Successful osimertinib rechallenge in a patient with advanced non-small cell lung cancer following osimertinib-induced interstitial lung disease after treatment with nivolumab
Osimertinib (Lungenkarzinom): Nutzenbewertung gemäß § 35a SGB V
Osimertinib-induced interstitial lung disease after treatment with anti-PD1 antibody
Therapeutic effect of osimertinib plus cranial radiotherapy compared to osimertinib alone in NSCLC patients with EGFR-activating mutations and brain metastases: a retrospective study
Afatinib plus osimertinib in the treatment of osimertinib-resistant non-small cell lung carcinoma: a phase I clinical trial
Osimertinib (NSCLC, adjuvant) : Nutzenbewertung gemäß § 35a SGB V
Osimertinib in Indian patients with T790M-positive advanced nonsmall cell lung cancer
Successful Rechallenge with Osimertinib following Osimertinib-Induced Ventricular Tachycardia: A Case Report
Osimertinib and palbociclib in an EGFR-mutated NSCLC with primary CDK4 amplification after progression under osimertinib
Editorial-T790M mutation and clinical outcomes with genuine osimertinib
Osimertinib in combination with anti-angiogenesis therapy presents a promising option for osimertinib-resistant non-small cell lung cancer
Correction: Osimertinib in combination with anti-angiogenesis therapy presents a promising option for osimertinib-resistant non-small cell lung cancer
Successful osimertinib rechallenge in a patient with advanced non-small cell lung cancer following osimertinib-induced interstitial lung disease after treatment with nivolumab
Osimertinib (Lungenkarzinom): Nutzenbewertung gemäß § 35a SGB V
Osimertinib-induced interstitial lung disease after treatment with anti-PD1 antibody
Therapeutic effect of osimertinib plus cranial radiotherapy compared to osimertinib alone in NSCLC patients with EGFR-activating mutations and brain metastases: a retrospective study
Afatinib plus osimertinib in the treatment of osimertinib-resistant non-small cell lung carcinoma: a phase I clinical trial
Osimertinib (NSCLC, adjuvant) : Nutzenbewertung gemäß § 35a SGB V